Home iSTAR Medical SA

iSTAR Medical SA

iSTAR Medical MIGS Device Studies: Highly Promising in Glaucoma Patients

The two-year final outcomes from STAR-I trial and six-month results from its European trial STAR-II have been accepted for presentation at the European Glaucoma Society meeting, now postponed to December 2020 following the Covid-19 pandemic.

iSTAR Medical MINIject

Company reports The STAR-I trial demonstrated that the implantation of MINIject resulted in a mean pressure of 15.0mmHgat 18-months, consistent with results reported at 1 year, and at a level expected to reduce the progression of glaucoma.

iSTAR Medical’s MINIject Maintains Exceptional Results in First-in-Human Trial One Year Post-Surgery ( STAR- I)

12/19/18: STAR-I trial demonstrated that the implantation of MINIject resulted in an average 32.6% IOP reduction to a mean of 15.6 mmHg at one year.

iSTAR Medical Reports MINIject Delivers Exceptional 6-Month Results in First-in-Human Trial

5/16/18: The results show MINIject to be safe and highly effective in achieving significant intraocular pressure (IOP) reduction in glaucoma patients.